Across TCGA pan-cancer cohorts, BMP2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BMP2 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher BMP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BMP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
THYM, PRAD, and UCEC are the cancer types where BMP2 Mutation most reproducibly stratifies survival.